Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 208

1.

Cancer-cell death ironed out.

Fennell D.

Nature. 2019 Aug;572(7769):314-315. doi: 10.1038/d41586-019-02218-y. No abstract available.

PMID:
31406306
2.

A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trial.

Belderbos RA, Baas P, Berardi R, Cornelissen R, Fennell DA, van Meerbeeck JP, Scherpereel A, Vroman H, Aerts JGJV.

Transl Lung Cancer Res. 2019 Jun;8(3):280-285. doi: 10.21037/tlcr.2019.05.05.

3.

Reply to K. Masuda et al.

Fennell DA, Taylor P, Gilligan D, Nakano T, Scherpereel A, Pavlakis N, van Meerbeeck JP, Aerts JGJV, Nowak AK, Kindler H, Baas P.

J Clin Oncol. 2019 Jul 22:JCO1901208. doi: 10.1200/JCO.19.01208. [Epub ahead of print] No abstract available.

PMID:
31329517
4.

Pathologic Considerations and Standardization in Mesothelioma Clinical Trials.

Tsao MS, Carbone M, Galateau-Salle F, Moreira AL, Nicholson AG, Roden AC, Adjei AA, Aubry MC, Fennell DA, Gomez D, Harpole D, Hesdorffer M, Hirsch FR, Liu G, Malik S, Nowak A, Peikert T, Salgia R, Szlosarek P, Taioli E, Yang H, Tsao A, Mansfield AS.

J Thorac Oncol. 2019 Jun 28. pii: S1556-0864(19)30502-7. doi: 10.1016/j.jtho.2019.06.020. [Epub ahead of print]

PMID:
31260832
5.

Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial.

Scagliotti GV, Gaafar R, Nowak AK, Nakano T, van Meerbeeck J, Popat S, Vogelzang NJ, Grosso F, Aboelhassan R, Jakopovic M, Ceresoli GL, Taylor P, Orlandi F, Fennell DA, Novello S, Scherpereel A, Kuribayashi K, Cedres S, Sørensen JB, Pavlakis N, Reck M, Velema D, von Wangenheim U, Kim M, Barrueco J, Tsao AS.

Lancet Respir Med. 2019 Jul;7(7):569-580. doi: 10.1016/S2213-2600(19)30139-0. Epub 2019 May 15.

PMID:
31103412
6.

A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma.

van Brummelen EMJ, Levchenko E, Dómine M, Fennell DA, Kindler HL, Viteri S, Gadgeel S, López PG, Kostorov V, Morgensztern D, Orlov S, Zauderer MG, Vansteenkiste JF, Baker-Neblett K, Vasquez J, Wang X, Bellovin DI, Schellens JHM, Yan L, Mitrica I, DeYoung MP, Trigo J.

Invest New Drugs. 2019 May 7. doi: 10.1007/s10637-019-00783-7. [Epub ahead of print]

PMID:
31065954
7.

When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?

Baird AM, Easty D, Jarzabek M, Shiels L, Soltermann A, Klebe S, Raeppel S, MacDonagh L, Wu C, Griggs K, Kirschner MB, Stanfill B, Nonaka D, Goparaju CM, Murer B, Fennell DA, O'Donnell DM, Barr MP, Mutti L, Reid G, Finn S, Cuffe S, Pass HI, Opitz I, Byrne AT, O'Byrne KJ, Gray SG.

Front Endocrinol (Lausanne). 2019 Feb 26;10:89. doi: 10.3389/fendo.2019.00089. eCollection 2019.

8.

Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study.

Fennell DA, Baas P, Taylor P, Nowak AK, Gilligan D, Nakano T, Pachter JA, Weaver DT, Scherpereel A, Pavlakis N, van Meerbeeck JP, Cedrés S, Nolan L, Kindler H, Aerts JGJV.

J Clin Oncol. 2019 Apr 1;37(10):790-798. doi: 10.1200/JCO.2018.79.0543. Epub 2019 Feb 20.

PMID:
30785827
9.

Sewer Sediment Bacterial Communities Suggest Potential to Transform Persistent Organic Pollutants.

Krumins V, Sun W, Guo J, Capozzi S, Fennell DE, Rodenburg LA.

Water Environ Res. 2018 Dec 1;90(12):2022-2029. doi: 10.2175/106143017X15131012188259.

PMID:
30538010
10.

Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation.

Tsao AS, Lindwasser OW, Adjei AA, Adusumilli PS, Beyers ML, Blumenthal GM, Bueno R, Burt BM, Carbone M, Dahlberg SE, de Perrot M, Fennell DA, Friedberg J, Gill RR, Gomez DR, Harpole DH Jr, Hassan R, Hesdorffer M, Hirsch FR, Hmeljak J, Kindler HL, Korn EL, Liu G, Mansfield AS, Nowak AK, Pass HI, Peikert T, Rimner A, Robinson BWS, Rosenzweig KE, Rusch VW, Salgia R, Sepesi B, Simone CB 2nd, Sridhara R, Szlosarek P, Taioli E, Tsao MS, Yang H, Zauderer MG, Malik SM.

J Thorac Oncol. 2018 Nov;13(11):1655-1667. doi: 10.1016/j.jtho.2018.08.2036. Epub 2018 Sep 25.

PMID:
30266660
11.

Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma.

Fennell DA.

J Thorac Oncol. 2018 Oct;13(10):1436-1437. doi: 10.1016/j.jtho.2018.07.007. No abstract available.

PMID:
30244849
12.

Diastereoisomer-Specific Biotransformation of Hexabromocyclododecanes by a Mixed Culture Containing Dehalococcoides mccartyi Strain 195.

Zhong Y, Wang H, Yu Z, Geng X, Chen C, Li D, Zhu X, Zhen H, Huang W, Fennell DE, Young LY, Peng P.

Front Microbiol. 2018 Jul 30;9:1713. doi: 10.3389/fmicb.2018.01713. eCollection 2018.

13.

Using positive matrix factorization to investigate microbial dehalogenation of chlorinated benzenes in groundwater at a historically contaminated site.

Capozzi SL, Rodenburg LA, Krumins V, Fennell DE, Mack EE.

Chemosphere. 2018 Nov;211:515-523. doi: 10.1016/j.chemosphere.2018.07.180. Epub 2018 Jul 31.

PMID:
30086528
14.

Targeting the tumour vasculature in mesothelioma.

Fennell DA.

Lancet Oncol. 2018 Jun;19(6):723-724. doi: 10.1016/S1470-2045(18)30248-1. Epub 2018 May 9. No abstract available.

PMID:
29753701
15.

CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial.

Fennell DA, Kirkpatrick E, Cozens K, Nye M, Lester J, Hanna G, Steele N, Szlosarek P, Danson S, Lord J, Ottensmeier C, Barnes D, Hill S, Kalevras M, Maishman T, Griffiths G.

Trials. 2018 Apr 18;19(1):233. doi: 10.1186/s13063-018-2602-y.

16.

BTS guideline for the investigation and management of malignant pleural mesothelioma.

Woolhouse I, Bishop L, Darlison L, de Fonseka D, Edey A, Edwards J, Faivre-Finn C, Fennell DA, Holmes S, Kerr KM, Nakas A, Peel T, Rahman NM, Slade M, Steele J, Tsim S, Maskell NA.

BMJ Open Respir Res. 2018 Feb 14;5(1):e000266. doi: 10.1136/bmjresp-2017-000266. eCollection 2018.

17.

Progress in the Management of Malignant Pleural Mesothelioma in 2017.

McCambridge AJ, Napolitano A, Mansfield AS, Fennell DA, Sekido Y, Nowak AK, Reungwetwattana T, Mao W, Pass HI, Carbone M, Yang H, Peikert T.

J Thorac Oncol. 2018 May;13(5):606-623. doi: 10.1016/j.jtho.2018.02.021. Epub 2018 Mar 8. Review.

18.

British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma.

Woolhouse I, Bishop L, Darlison L, De Fonseka D, Edey A, Edwards J, Faivre-Finn C, Fennell DA, Holmes S, Kerr KM, Nakas A, Peel T, Rahman NM, Slade M, Steele J, Tsim S, Maskell NA.

Thorax. 2018 Mar;73(Suppl 1):i1-i30. doi: 10.1136/thoraxjnl-2017-211321. No abstract available.

PMID:
29444986
19.

Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy.

Manegold C, Adjei A, Bussolino F, Cappuzzo F, Crino L, Dziadziuszko R, Ettinger D, Fennell D, Kerr K, Le Chevalier T, Leighl N, Papotti M, Paz-Ares L, Pérol M, Peters S, Pirker R, Quoix E, Reck M, Smit E, Vokes E, van Zandwijk N, Zhou C.

ESMO Open. 2017 Jan 13;1(6):e000118. doi: 10.1136/esmoopen-2016-000118. eCollection 2016.

20.

Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells.

Kolluri KK, Alifrangis C, Kumar N, Ishii Y, Price S, Michaut M, Williams S, Barthorpe S, Lightfoot H, Busacca S, Sharkey A, Yuan Z, Sage EK, Vallath S, Le Quesne J, Tice DA, Alrifai D, von Karstedt S, Montinaro A, Guppy N, Waller DA, Nakas A, Good R, Holmes A, Walczak H, Fennell DA, Garnett M, Iorio F, Wessels L, McDermott U, Janes SM.

Elife. 2018 Jan 18;7. pii: e30224. doi: 10.7554/eLife.30224.

21.

Corrigendum: Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.

Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, Moore DA, Veeriah S, Rosenthal R, Marafioti T, Kirkizlar E, Watkins TBK, McGranahan N, Ward S, Martinson L, Riley J, Fraioli F, Al Bakir M, Grönroos E, Zambrana F, Endozo R, Bi WL, Fennessy FM, Sponer N, Johnson D, Laycock J, Shafi S, Czyzewska-Khan J, Rowan A, Chambers T, Matthews N, Turajlic S, Hiley C, Lee SM, Forster MD, Ahmad T, Falzon M, Borg E, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Hafez D, Naik A, Ganguly A, Kareht S, Shah R, Joseph L, Quinn AM, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Oukrif D, Akarca AU, Hartley JA, Lowe HL, Lock S, Iles N, Bell H, Ngai Y, Elgar G, Szallasi Z, Schwarz RF, Herrero J, Stewart A, Quezada SA, Peggs KS, Van Loo P, Dive C, Lin CJ, Rabinowitz M, Aerts HJWL, Hackshaw A, Shaw JA, Zimmermann BG, Swanton C.

Nature. 2018 Feb 8;554(7691):264. doi: 10.1038/nature25161. Epub 2017 Dec 20.

PMID:
29258292
22.

Analysis of airborne microbial communities using 16S ribosomal RNA: Potential bias due to air sampling stress.

Zhen H, Krumins V, Fennell DE, Mainelis G.

Sci Total Environ. 2018 Apr 15;621:939-947. doi: 10.1016/j.scitotenv.2017.10.154. Epub 2017 Nov 1.

23.

Management of Progressive Pulmonary Nodules Found during and outside of CT Lung Cancer Screening Studies.

Meyer M, Vliegenthart R, Henzler T, Buergy D, Giordano FA, Kostrzewa M, Rathmann N, Brustugun OT, Crino L, Dingemans AC, Dusmet M, Fennell D, Grunenwald D, Huber RM, Moniuszko M, Mornex F, Papotti M, Pilz L, Senan S, Syrigos K, Pérol M, Gray JE, Schabel C, van Meerbeeck JP, van Zandwijk N, Zhou CC, Manegold C, Voigt W, Roessner ED.

J Thorac Oncol. 2017 Dec;12(12):1755-1765. doi: 10.1016/j.jtho.2017.09.1956. Epub 2017 Sep 27. Review.

24.

miR-16: expanding the range of molecular targets in mesothelioma.

Fennell D.

Lancet Oncol. 2017 Oct;18(10):1296-1297. doi: 10.1016/S1470-2045(17)30596-X. Epub 2017 Sep 1. No abstract available.

PMID:
28870616
25.

Forensic Analysis of Polychlorinated Dibenzo-p-Dioxin and Furan Fingerprints to Elucidate Dechlorination Pathways.

Rodenburg LA, Dewani Y, Häggblom MM, Kerkhof LJ, Fennell DE.

Environ Sci Technol. 2017 Sep 19;51(18):10485-10493. doi: 10.1021/acs.est.7b02705. Epub 2017 Aug 30.

PMID:
28796943
26.

Novel insights into mesothelioma biology and implications for therapy.

Yap TA, Aerts JG, Popat S, Fennell DA.

Nat Rev Cancer. 2017 Jul 25;17(8):475-488. doi: 10.1038/nrc.2017.42. Review.

PMID:
28740119
27.

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.

Maio M, Scherpereel A, Calabrò L, Aerts J, Cedres Perez S, Bearz A, Nackaerts K, Fennell DA, Kowalski D, Tsao AS, Taylor P, Grosso F, Antonia SJ, Nowak AK, Taboada M, Puglisi M, Stockman PK, Kindler HL.

Lancet Oncol. 2017 Sep;18(9):1261-1273. doi: 10.1016/S1470-2045(17)30446-1. Epub 2017 Jul 17.

PMID:
28729154
28.

Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.

Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, Moore DA, Veeriah S, Rosenthal R, Marafioti T, Kirkizlar E, Watkins TBK, McGranahan N, Ward S, Martinson L, Riley J, Fraioli F, Al Bakir M, Grönroos E, Zambrana F, Endozo R, Bi WL, Fennessy FM, Sponer N, Johnson D, Laycock J, Shafi S, Czyzewska-Khan J, Rowan A, Chambers T, Matthews N, Turajlic S, Hiley C, Lee SM, Forster MD, Ahmad T, Falzon M, Borg E, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Hafez D, Naik A, Ganguly A, Kareht S, Shah R, Joseph L, Marie Quinn A, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Oukrif D, Akarca AU, Hartley JA, Lowe HL, Lock S, Iles N, Bell H, Ngai Y, Elgar G, Szallasi Z, Schwarz RF, Herrero J, Stewart A, Quezada SA, Peggs KS, Van Loo P, Dive C, Lin CJ, Rabinowitz M, Aerts HJWL, Hackshaw A, Shaw JA, Zimmermann BG; TRACERx consortium; PEACE consortium, Swanton C.

Nature. 2017 Apr 26;545(7655):446-451. doi: 10.1038/nature22364. Erratum in: Nature. 2017 Dec 20;:.

29.

Tracking the Evolution of Non-Small-Cell Lung Cancer.

Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, Veeriah S, Shafi S, Johnson DH, Mitter R, Rosenthal R, Salm M, Horswell S, Escudero M, Matthews N, Rowan A, Chambers T, Moore DA, Turajlic S, Xu H, Lee SM, Forster MD, Ahmad T, Hiley CT, Abbosh C, Falzon M, Borg E, Marafioti T, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Shah R, Joseph L, Quinn AM, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Dentro S, Taniere P, O'Sullivan B, Lowe HL, Hartley JA, Iles N, Bell H, Ngai Y, Shaw JA, Herrero J, Szallasi Z, Schwarz RF, Stewart A, Quezada SA, Le Quesne J, Van Loo P, Dive C, Hackshaw A, Swanton C; TRACERx Consortium.

N Engl J Med. 2017 Jun 1;376(22):2109-2121. doi: 10.1056/NEJMoa1616288. Epub 2017 Apr 26.

30.

The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC.

Manegold C, Dingemans AC, Gray JE, Nakagawa K, Nicolson M, Peters S, Reck M, Wu YL, Brustugun OT, Crinò L, Felip E, Fennell D, Garrido P, Huber RM, Marabelle A, Moniuszko M, Mornex F, Novello S, Papotti M, Pérol M, Smit EF, Syrigos K, van Meerbeeck JP, van Zandwijk N, Chih-Hsin Yang J, Zhou C, Vokes E.

J Thorac Oncol. 2017 Feb;12(2):194-207. doi: 10.1016/j.jtho.2016.10.003. Epub 2016 Oct 8. Review.

31.

How does the timing of chemotherapy affect outcome following radical surgery for malignant pleural mesothelioma?

Sharkey AJ, O'Byrne KJ, Nakas A, Tenconi S, Fennell DA, Waller DA.

Lung Cancer. 2016 Oct;100:5-13. doi: 10.1016/j.lungcan.2016.07.023. Epub 2016 Jul 22.

PMID:
27597274
32.

Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial.

Szlosarek PW, Steele JP, Nolan L, Gilligan D, Taylor P, Spicer J, Lind M, Mitra S, Shamash J, Phillips MM, Luong P, Payne S, Hillman P, Ellis S, Szyszko T, Dancey G, Butcher L, Beck S, Avril NE, Thomson J, Johnston A, Tomsa M, Lawrence C, Schmid P, Crook T, Wu BW, Bomalaski JS, Lemoine N, Sheaff MT, Rudd RM, Fennell D, Hackshaw A.

JAMA Oncol. 2017 Jan 1;3(1):58-66. doi: 10.1001/jamaoncol.2016.3049.

PMID:
27584578
33.

KDM6B histone demethylase is an epigenetic regulator of estrogen receptor β expression in human pleural mesothelioma.

Manente AG, Pinton G, Zonca S, Tavian D, Habib T, Jithesh PV, Fennell D, Nilsson S, Moro L.

Epigenomics. 2016 Sep;8(9):1227-38. doi: 10.2217/epi-2016-0025. Epub 2016 Aug 16.

34.

Analysis of Gene Expression in 3D Spheroids Highlights a Survival Role for ASS1 in Mesothelioma.

Barbone D, Van Dam L, Follo C, Jithesh PV, Zhang SD, Richards WG, Bueno R, Fennell DA, Broaddus VC.

PLoS One. 2016 Mar 16;11(3):e0150044. doi: 10.1371/journal.pone.0150044. eCollection 2016.

35.

SIRT1 at the crossroads of AKT1 and ERβ in malignant pleural mesothelioma cells.

Pinton G, Zonca S, Manente AG, Cavaletto M, Borroni E, Daga A, Jithesh PV, Fennell D, Nilsson S, Moro L.

Oncotarget. 2016 Mar 22;7(12):14366-79. doi: 10.18632/oncotarget.7321.

36.

Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer.

Fennell DA, Summers Y, Cadranel J, Benepal T, Christoph DC, Lal R, Das M, Maxwell F, Visseren-Grul C, Ferry D.

Cancer Treat Rev. 2016 Mar;44:42-50. doi: 10.1016/j.ctrv.2016.01.003. Epub 2016 Feb 4. Review.

PMID:
26866673
37.

Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs.

Bayliss R, Choi J, Fennell DA, Fry AM, Richards MW.

Cell Mol Life Sci. 2016 Mar;73(6):1209-24. doi: 10.1007/s00018-015-2117-6. Epub 2016 Jan 11. Review.

38.

Circumventing HSP90 inhibitors via apoptosis block.

Fennell DA, Busacca S.

Oncoscience. 2015 Aug 20;2(9):747-8. eCollection 2015. No abstract available.

39.

Electrochemically driven extraction and recovery of ammonia from human urine.

Luther AK, Desloover J, Fennell DE, Rabaey K.

Water Res. 2015 Dec 15;87:367-77. doi: 10.1016/j.watres.2015.09.041. Epub 2015 Sep 30.

PMID:
26453942
40.

Identification of Anaerobic Aniline-Degrading Bacteria at a Contaminated Industrial Site.

Sun W, Li Y, McGuinness LR, Luo S, Huang W, Kerkhof LJ, Mack EE, Häggblom MM, Fennell DE.

Environ Sci Technol. 2015 Sep 15;49(18):11079-88. doi: 10.1021/acs.est.5b02166. Epub 2015 Aug 26.

PMID:
26280684
41.

Development of a dual-internal-reference technique to improve accuracy when determining bacterial 16S rRNA:16S rRNA gene ratio with application to Escherichia coli liquid and aerosol samples.

Zhen H, Krumins V, Fennell DE, Mainelis G.

J Microbiol Methods. 2015 Oct;117:113-21. doi: 10.1016/j.mimet.2015.07.023. Epub 2015 Aug 1.

PMID:
26241659
42.

Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Baas P, Fennell D, Kerr KM, Van Schil PE, Haas RL, Peters S; ESMO Guidelines Committee.

Ann Oncol. 2015 Sep;26 Suppl 5:v31-9. doi: 10.1093/annonc/mdv199. Epub 2015 Jul 28. No abstract available.

PMID:
26223247
43.

Resistance to HSP90 inhibition involving loss of MCL1 addiction.

Busacca S, Law EW, Powley IR, Proia DA, Sequeira M, Le Quesne J, Klabatsa A, Edwards JM, Matchett KB, Luo JL, Pringle JH, El-Tanani M, MacFarlane M, Fennell DA.

Oncogene. 2016 Mar 24;35(12):1483-92. doi: 10.1038/onc.2015.213. Epub 2015 Jun 22.

44.

A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1).

Ramalingam S, Goss G, Rosell R, Schmid-Bindert G, Zaric B, Andric Z, Bondarenko I, Komov D, Ceric T, Khuri F, Samarzija M, Felip E, Ciuleanu T, Hirsh V, Wehler T, Spicer J, Salgia R, Shapiro G, Sheldon E, Teofilovici F, Vukovic V, Fennell D.

Ann Oncol. 2015 Aug;26(8):1741-8. doi: 10.1093/annonc/mdv220. Epub 2015 May 21.

PMID:
25997818
45.

Demographics, management and survival of patients with malignant pleural mesothelioma in the National Lung Cancer Audit in England and Wales.

Beckett P, Edwards J, Fennell D, Hubbard R, Woolhouse I, Peake MD.

Lung Cancer. 2015 Jun;88(3):344-8. doi: 10.1016/j.lungcan.2015.03.005. Epub 2015 Mar 30.

PMID:
25863904
46.

Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial.

Krug LM, Kindler HL, Calvert H, Manegold C, Tsao AS, Fennell D, Öhman R, Plummer R, Eberhardt WE, Fukuoka K, Gaafar RM, Lafitte JJ, Hillerdal G, Chu Q, Buikhuisen WA, Lubiniecki GM, Sun X, Smith M, Baas P.

Lancet Oncol. 2015 Apr;16(4):447-56. doi: 10.1016/S1470-2045(15)70056-2. Epub 2015 Mar 20. Erratum in: Lancet Oncol. 2015 May;16(5):e199.

PMID:
25800891
47.

Perspectives of novel imaging techniques for staging, therapy response assessment, and monitoring of surveillance in lung cancer: summary of the Dresden 2013 Post WCLC-IASLC State-of-the-Art Imaging Workshop.

Henzler T, Goldstraw P, Wenz F, Pirker R, Weder W, Apfaltrer P, Meyer M, Buesing K, Crino L, Fennell D, Fink C, Grunenwald D, Manegold C, Pilz L, Schoenberg SO, Suresh S, Vansteenkiste J, Voigt W, Wängler B, Schmid-Bindert G.

J Thorac Oncol. 2015 Feb;10(2):237-49. doi: 10.1097/JTO.0000000000000412.

48.
49.

Association between gene expression profiles and clinical outcome of pemetrexed-based treatment in patients with advanced non-squamous non-small cell lung cancer: exploratory results from a phase II study.

Fennell DA, Myrand SP, Nguyen TS, Ferry D, Kerr KM, Maxwell P, Moore SD, Visseren-Grul C, Das M, Nicolson MC.

PLoS One. 2014 Sep 24;9(9):e107455. doi: 10.1371/journal.pone.0107455. eCollection 2014.

50.

Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: an individual patient pooled analysis of 10 European Organisation for Research and Treatment of Cancer Lung Cancer Group studies and an independent study validation.

Hasan B, Greillier L, Pallis A, Menis J, Gaafar R, Sylvester R, Fennell DA, Baas P, Surmont V, Van Meerbeeck JP, O'brien ME.

Eur J Cancer. 2014 Nov;50(16):2771-82. doi: 10.1016/j.ejca.2014.07.020. Epub 2014 Aug 21.

PMID:
25155251

Supplemental Content

Loading ...
Support Center